AB3279
Anti-Hexokinase Type II Antibody
Chemicon®, from rabbit
Sinónimos:
HK II
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Anti-Hexokinase Type II Antibody, Chemicon®, from rabbit
biological source
rabbit
conjugate
unconjugated
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
rat, human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunocytochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... HK2(3099)
Analysis Note
Control
insulin-responsive tissues such as skeletal muscle
insulin-responsive tissues such as skeletal muscle
Application
Anti-Hexokinase Type II Antibody is an antibody against Hexokinase Type II for use in ELISA, IC & WB.
Research Category
Metabolism
Metabolism
Research Sub Category
Enzymes & Biochemistry
Enzymes & Biochemistry
Western Blot: 1:5,000-1:10,000.
Immunocytochemistry using indirect immunofluorescence.
ELISA
Optimal working dilutions must be determined by the end user.
Immunocytochemistry using indirect immunofluorescence.
ELISA
Optimal working dilutions must be determined by the end user.
Biochem/physiol Actions
Reacts with the Type II isozyme of rat hexokinase (102 kDa). No reactivity with the Type I or Type III isozymes of rat hexokinase by immunoblot or ELISA. Reactivity with human and hamster Type II isozyme has been confirmed by immunoblotting, and reactivity with Type II isozyme from other mammalian species is expected.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
102 kDa
Immunogen
Recombinant rat Type II hexokinase.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
Immunodepleted Serum
Liquid. Partially Purified rabbit Serum. Antibodies reactive with the Type I isozyme were present in the original antiSerum; these were removed by affinity chromatography on a column of immobilized Type I isozyme, and the affinity-depleted Serum restored to original volume.
Preparation Note
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Clase de almacenamiento
10 - Combustible liquids
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Yuya Nogami et al.
BMC medical imaging, 16, 31-31 (2016-04-27)
We report two cases of anisakiasis lesions that were initially suspected to be recurrence of gynecological cancer by positron emission tomography-computed tomography (PET-CT). Both cases were extragastrointestinal anisakiasis that is very rare. The first case was a patient with endometrial
Chung-Ling Lu et al.
PloS one, 10(3), e0121046-e0121046 (2015-03-26)
A unique feature of cancer cells is to convert glucose into lactate to produce cellular energy, even under the presence of oxygen. Called aerobic glycolysis [The Warburg Effect] it has been extensively studied and the concept of aerobic glycolysis in
Wenshan Hao et al.
The Journal of biological chemistry, 285(17), 12647-12654 (2010-01-30)
Cancer cells constantly adapt to oxidative phosphorylation (OXPHOS) suppression resulting from hypoxia or mitochondria defects. Under the OXPHOS suppression, AMP-activated protein kinase (AMPK) regulates global metabolism adjustments, but its activation has been found to be transient. Whether cells can maintain
Santosh K Maurya et al.
Cell reports, 24(11), 2919-2931 (2018-09-13)
The major objective of this study was to understand the molecular basis of how sarcolipin uncoupling of SERCA regulates muscle oxidative metabolism. Using genetically engineered sarcolipin (SLN) mouse models and primary muscle cells, we demonstrate that SLN plays a crucial
Stephanie E Siegmund et al.
Human molecular genetics, 26(23), 4588-4605 (2017-10-04)
Mitochondrial disorders affecting oxidative phosphorylation (OxPhos) are caused by mutations in both the nuclear and mitochondrial genomes. One promising candidate for treatment is the drug rapamycin, which has been shown to extend lifespan in multiple animal models, and which was
Contenido relacionado
RABBIT ANTI-TYPE II HEXOKINASE
Número de artículo de comercio global
| SKU | GTIN |
|---|---|
| AB3279 | 04053252589539 |
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico